Fig. 4

Hazard ratio (95% confidence interval) and Kaplan Meier curves for the association of acylcarnitines with lymph node progression. a Hazard ratios and 95% confidence interval (CI) for the association of the complete panel of acylcarnitines with the risk of lymph node progression. Groups (lower and higher risk) were separate by median cut-off (suffix “_med”) of the normalized abundances for each molecule. C4 = butyrylcarnitine, C4_M = methylmalonylcarnitine. b Lymph node progression-free survival calculated by the Kaplan Meier method for L-carnitine (C0). Groups are defined by median-cut off of normalized abundances of high L-carnitine (C0 High, red dotted line) versus low L-carnitne (C0 Low, blue solid line). P-value was estimated with Log-Rank test. c Lymph node progression free survival calculated by the Kaplan Meier method for isovalerylcarnitine (C5). Groups are defined by median-cut off of normalized abundances (versus L-carnitine) of high isovalerylcarnitine (C5 High, red dotted line) vs low isovelrylcarnitne (C5 Low, blue solid line). P-value was estimated with Log-Rank test. For statistical details see Methods section